Emerging data suggest Retatru tide , a dual activator targeting both GLP-1 and GIP , appears to offer a notable step forward for weight loss . Preliminary patient trials have demonstrated considerable reductions in visceral mass , conceivably outperforming other weight-loss treatments. Despite this, further assessment is necessary to fully understa